by Lisa Stiffler on Jul 31, 2026 at 9:15 am July 31, 2026 at 9:15 am
Less than a year after emerging from stealth operations with $12.7 million and partnerships with pharmaceutical giants, Seattle-based biotech startup Accipiter Biosciences has added $10.5 million to its funding total. The new cash will let the company move faster on promising drug candidates.
“We could have stuck with the original plan and been just fine,” said Matthew Bick, Accipiter Bio’s co-founder and CEO. “But we thought we’d rather capitalize on the progress we’ve made now and diversify our clinical portfolio.”
The team has grown to 22 people and includes researchers who…
Read the full article at GEEKWIRE.COM


